Dr. Chris Kirk is co-founder, president, and chief scientific officer of Kezar Life Sciences. Dr. Kirk has worked in the biotechnology industry since 2001 and has held numerous positions in drug discovery and development. Prior to forming Kezar, Chris was the Vice President of Research at Onyx Pharmaceuticals, where he played a key role in the discovery and development of two proteasome inhibitors, carfilzomib (KYPROLIS™) and oprozomib. Chris joined Onyx via the acquisition of Proteolix in 2009, where he was the one of the first scientific hires after their Series A funding.
Chris received his BS from U.C. Davis and his PhD in Cellular and Molecular Biology from the University of Michigan in 1999.